Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: Impact on outcome and chemotherapy effects

Hugo J A Adams*, John M H De Klerk, Rob Fijnheer, Ben G F Heggelman, Stefan V. Dubois, Rutger A J Nievelstein, Thomas C. Kwee

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: There is a lack of data on the effect of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy on brain glucose metabolism of diffuse large B-cell lymphoma (DLBCL) patients, as measured by 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET). Moreover, the prognostic value of brain glucose metabolism measurements is currently unknown. Purpose: To investigate the use of FDG-PET for measurement of brain glucose metabolism in R-CHOP-treated DLBCL patients, and to assess its prognostic value. Material and Methods: This retrospective study included DLBCL patients who underwent FDG-PET including the brain. FDG-PET metabolic volume products (MVPs) of the entire brain, cerebral cortex, basal ganglia, and cerebellum were measured, before and after R-CHOP therapy. Whole-body total lesion glycolysis (TLG) was also measured. Results: Thirty-eight patients were included, of whom 18 had an appropriate end-of-treatment FDG-PET scan. There were no significant differences (P>0.199) between pre-and post-treatment brain glucose metabolism metrics. Low basal ganglia MVP was associated with a significantly worse progression-free survival (PFS) and overall survival (OS) (P0.020 and P0.032), and low cerebellar MVP was associated with a significantly worse OS (P0.034). There were nonsignificant very weak correlations between pretreatment brain glucose metabolism metrics and TLG. In the multivariate Cox regression, only the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) remained an independent predictor of PFS (hazard ratio 3.787, P0.007) and OS (hazard ratio 2.903, P0.0345). Conclusion: Brain glucose metabolism was not affected by R-CHOP therapy. Low pretreatment brain glucose metabolism was associated with a worse outcome, but did not surpass the predictive value of the NCCN-IPI.

Original languageEnglish
Pages (from-to)733-741
Number of pages9
JournalActa Radiologica
Volume57
Issue number6
Early online date2015
DOIs
Publication statusPublished - 2016

Keywords

  • Brain
  • Chemotherapy
  • Diffuse large B-cell lymphoma
  • FDG-PET
  • R-CHOP

Fingerprint

Dive into the research topics of 'Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: Impact on outcome and chemotherapy effects'. Together they form a unique fingerprint.

Cite this